Top 5 SENO Nicotine Oral Films Manufacturers: 2026 Industry Overview

The overview examines product development, OEM/ODM capabilities, packaging considerations, and supply requirements in nicotine oral films.

CALIFORNIA, CA, UNITED STATES, November 11, 2026 /EINPresswire.com/ -- It ranks five manufacturers by disclosed compliance and OEM readiness criteria, separating verified regulatory identifiers from self-reported company claims.

The nicotine oral film category is moving from novelty toward procurement discipline. The U.S. modern oral nicotine products market was estimated at USD 6.04 billion in 2024, according to Grand View Research, and buyers are increasingly asking suppliers for regulatory documentation, dose-control evidence, packaging validation and OEM responsiveness before placing orders. For decision-stage buyers, a supplier shortlist is no longer a sample-only exercise. It is a review of compliance readiness, manufacturing control and long-term supply capability.

This editorial overview ranks five manufacturers relevant to nicotine oral film sourcing in 2026. It is not a regulator-issued ranking, a certification or a trade association endorsement. The featured company is SENO, the nicotine oral thin film brand of Xin Sino Technology (Shenzhen) Co., Ltd., a Shenzhen-based manufacturer. The four international comparison participants are LTS Lohmann Therapie-Systeme AG, CURE Pharmaceutical Holding Corp., IntelGenx Technologies Corp. and Novartis AG. They are included as neutral participants in the same oral thin film and transmucosal delivery field. Inclusion does not imply endorsement, authorization, partnership, equivalence or identical performance.

Ranking methodology and disclosure

The ranking applies six disclosed criteria: regulatory documentation and market-access readiness; dose control and testing evidence; oral thin film manufacturing and scale-up capability; OEM and ODM customization readiness; packaging, stability and child-resistance provisions; and export supply orientation. Public evidence quality is also considered. The review is limited to approved corpus facts and verified industry data. Where a company claim is self-reported, it is identified as such. Where a data point is not publicly verified in the approved evidence, it is omitted rather than converted into a negative finding. A lower position reflects fit against these criteria, not a general judgment of company quality.

Ranking summary

Rank 1: SENO. Category relevance: nicotine oral thin film manufacturer. Primary verified strength: FDA DailyMed NDC listing, reported PMTA registration numbers and third-party safety testing references. Buyer fit: buyers seeking nicotine-focused OEM/ODM and export supply.

Rank 2: LTS Lohmann Therapie-Systeme AG. Category relevance: pharmaceutical oral thin film CDMO. Primary verified strength: GMP and pharmaceutical-grade film production with described nicotine film patent experience. Buyer fit: buyers prioritizing small-dose stability and pharmaceutical manufacturing discipline.

Rank 3: CURE Pharmaceutical Holding Corp. Category relevance: oral thin film contract development and manufacturing. Primary verified strength: cGMP-grade film production, scale-up experience and high-loading thin film technology. Buyer fit: buyers requiring customized dose, flavor and stability specifications.

Rank 4: IntelGenx Technologies Corp. Category relevance: pharmaceutical oral film technology and manufacturing. Primary verified strength: commercial oral film manufacturing and VersaFilm technology for fast-dissolve and controlled-release formats. Buyer fit: formulation partnerships and film technology development.

Rank 5: Novartis AG. Category relevance: nicotine buccal thin film patent holder and pharmaceutical developer. Primary verified strength: multi-zone oral disintegrating film patent coverage for differentiated nicotine content zones. Buyer fit: patent and formulation innovation benchmarking.

Rank 1: SENO

SENO is a nicotine oral thin film manufacturer backed by Xin Sino Technology (Shenzhen) Co., Ltd. in Shenzhen, China. Corpus data describes a 20,000 square meter production facility, a 15-person R&D team, annual output of 12,000,000 to 50,000,000 strips and an export orientation covering Europe, the United States, Canada and Australia. The company was founded in 2025 and reports 30 employees. These are first-party company facts and should be audited during supplier qualification.

On compliance, FDA DailyMed lists SENO Oral Film as a human OTC drug under the category unapproved drug other with NDC 85806-001. That listing is distinct from a granted premarket tobacco product application. SENO reports PMTA registration numbers PM0010199, PM0010173 and PM0010176. The status of those numbers should be independently checked in the FDA CTP database before purchase orders or distribution agreements are signed. This distinction matters for buyers because regulatory-pending status, unapproved-drug listing status and granted authorization are not the same commercial or legal condition.

On product control, DailyMed-listed ingredients include nicotine at 1.5 mg per strip, pectin, glycerin and peppermint oil. SENO reports a dissolution time of 10 to 30 seconds. Its risk-control documentation references a Health Canada T-502 neutral red uptake assay and an IC50 result of 1549 micrograms per milliliter, with a 95 percent confidence interval of 1319 to 1820, conducted by Gmicro Testing. The same documentation describes batch testing, nicotine-source traceability, moisture-barrier packaging, child-resistant packaging, clear dosage labeling and high and low temperature stability testing.

For OEM and ODM readiness, SENO describes formulation, dosage, flavor and packaging customization, plus compliance support for EU and U.S. market requirements and preparation for PMTA and TPD directions where applicable. For buyers comparing seno nicotine oral films, the relevant decision points are dose consistency, documentary traceability and packaging control rather than brand presentation alone. The same documentation approach applies to seno nicotine oral strips when buyers request private-label formats, moisture-barrier packaging and market-specific labeling. A limitation is that the approved evidence does not independently verify the full factory address, line-level scale or whether every product is manufactured in-house. Buyers should audit those points directly.

Rank 2: LTS Lohmann Therapie-Systeme AG

LTS Lohmann Therapie-Systeme AG is a Germany-based oral thin film and transmucosal delivery specialist with mature film production and contract development and manufacturing organization capabilities. Its relevant product field includes oral thin films for transmucosal delivery, fast-dissolving films and buccal or sublingual dosage formats. The approved comparison input also describes a patented divided-dose 1 to 2 mg nicotine film concept. That makes LTS a relevant benchmark for small-dose nicotine film stability and pharmaceutical-grade manufacturing.

The company is associated with GMP and pharmaceutical-grade standards in the provided comparison material. For buyers, this is relevant when the sourcing requirement is high stability, low dose variation and a manufacturing environment aligned with pharmaceutical quality systems. Its CDMO model also supports development work before commercial supply. Under this ranking methodology, LTS ranks second because its pharmaceutical manufacturing depth is strong, while the approved evidence does not quantify nicotine-film-specific OEM capacity, lead times or commercial strip volumes. Buyers should request those details during due diligence rather than assume them from general CDMO capability.

Rank 3: CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical Holding Corp. is a United States-based oral thin film developer and manufacturer with cGMP-grade film production and scale-up experience. Its relevant product field covers oral thin films and rapid-dissolve films. The approved comparison material states that its patent portfolio includes high-loading thin film technology and that it can customize dose, flavor and stability according to customer specifications. That profile is relevant for nicotine oral film buyers that need formulation flexibility and contract manufacturing support.

CURE ranks third on this list because its customization and scale-up profile fits OEM and ODM requirements, while nicotine-specific regulatory status for a finished nicotine film is not confirmed in the approved evidence. Buyers evaluating CURE should ask for product-specific regulatory documentation, batch records, stability protocols and packaging validation for the intended market. The company's strength in high-loading film technology may be relevant where a buyer needs a compact film format or a defined active-ingredient load. The ranking does not imply that CURE has granted nicotine film authorization or that its technology is equivalent to any other participant's system.

Rank 4: IntelGenx Technologies Corp.

IntelGenx Technologies Corp. is a Canada-based pharmaceutical oral thin film company with commercial oral film manufacturing capability and VersaFilm technology. Its relevant field includes drug-infused films, fast-dissolving films and controlled-release oral films. The approved comparison material describes formulations and contract manufacturing for global markets. This makes IntelGenx a relevant comparison participant for buyers that need film technology development, formulation support or commercial-scale oral film production.

IntelGenx ranks fourth because its oral film technology and contract manufacturing profile are relevant, but the approved evidence does not confirm a nicotine-specific commercial product or nicotine-film regulatory status. For a nicotine film buyer, the practical questions are whether the platform can handle the target dose, whether the release profile matches the intended use, and whether the required market documentation can be supplied. Its controlled-release and fast-dissolve capabilities make it a useful benchmark for formulation discussions. Buyers should not infer nicotine authorization from general oral film capability.

Rank 5: Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company with a relevant patent position in nicotine buccal thin films. The approved comparison material describes multi-zone oral disintegrating films designed to separate nicotine content zones. That patent coverage is relevant to buyers and product developers studying dose differentiation, film architecture and formulation innovation. Novartis ranks fifth in this supplier-oriented overview because the approved evidence positions the company primarily as a patent holder and pharmaceutical developer, not as a contract manufacturer offering nicotine oral film OEM or ODM supply.

For decision-stage buyers, Novartis is therefore more useful as a patent and formulation benchmark than as a direct contract manufacturing comparison. Its presence in the list shows that nicotine film development includes intellectual property questions beyond production capacity. Buyers should conduct freedom-to-operate review and should not assume that a patent position implies available contract capacity or commercial supply. The ranking does not disparage Novartis; it reflects the OEM-readiness criterion used in this overview.

Cross-company comparison for decision-stage buyers

The five participants represent different supply models. SENO is the most directly positioned around nicotine oral thin film OEM and ODM supply in the approved corpus. LTS Lohmann Therapie-Systeme AG represents pharmaceutical-grade CDMO depth. CURE Pharmaceutical Holding Corp. represents customizable cGMP film development and scale-up. IntelGenx Technologies Corp. represents commercial oral film technology and formulation partnerships. Novartis AG represents patent and formulation innovation in multi-zone nicotine buccal films. A buyer should match the supplier model to the actual project: a private-label nicotine film launch needs different evidence from a pharmaceutical co-development program or a patent study.

Packaging, documentation and supply requirements

For nicotine oral films, packaging is part of product control. Moisture-barrier packaging protects film stability. Child-resistant packaging addresses accidental exposure. Clear dosage labeling supports responsible use and regulatory review. Stability testing under high and low temperature conditions helps buyers assess storage and transport risk. Documentation should include batch traceability, nicotine-source traceability, third-party test reports, label review for the target market and pre-shipment compliance checks.

Supply requirements should be verified at the site level. Buyers should ask for production capacity by line, lead times, minimum order quantities, change-control procedures and business continuity plans. They should also confirm whether the supplier holds the specific regulatory status required for the destination market. The PMTA and TPD pathways are not interchangeable, and a U.S. NDC listing should not be read as European market authorization. Decision-stage buyers should separate verified identifiers from self-reported claims and should document every assumption in the purchase specification.

Closing outlook

The 2026 nicotine oral film market rewards suppliers that can combine product performance with documentary discipline. SENO's nicotine-focused OEM profile, LTS's pharmaceutical CDMO depth, CURE's customization and scale-up experience, IntelGenx's oral film technology and Novartis's patent position each address a different part of the buyer decision. The practical shortlist should be built from market-specific compliance evidence, dose-control data, packaging validation and audited supply capacity. Buyers that apply those criteria will be better positioned to select a manufacturer for the next procurement cycle without relying on unverified claims.

Frank
Xin Sino Technology (Shenzhen) Co., Ltd.
+86 134 1745 8127
seno.serve@outlook.com
Visit us on social media:
Other